Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

APRIL 16, 2023

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. According to the results of an interim analysis conducted after a median follow-up of 17.4

Therapies 130

Therapies Medical Schools Trials Treatment 130

Drug Discovery World

OCTOBER 13, 2023

Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new artificial intelligence (AI) tool named EVEscape that can predict new viral variants before they emerge. million funding from UK Research and Innovation (UKRI).

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

JULY 5, 2024

The trial met its primary endpoint with 87% of the patient cohort showing a reduction in the risk of flare-ups compared to the placebo therapy. The trial also met all key secondary endpoints including annualised flare rate; flare-free, treatment-free complete remission; and flare-free, corticosteroid-free complete remission.

Treatment 147

Treatment Medical Schools Trials Clinical Trials 147

Broad Institute

AUGUST 7, 2024

Core institute members have a major research presence at Broad, and remain full members of their home institution (MIT, Harvard University, or one of Harvard’s primary teaching hospitals). Anna Greka ’s research focuses on fundamental mechanisms of cellular dysfunction in genetic diseases with a focus on membrane proteins.

Medical Schools 90

Medical Schools Hospitals Bioinformatics Vaccine 90

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Discovery World

JUNE 12, 2024

Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. The research project will also explore proteomic pathways associated with treatment response and immune-related adverse events (irAEs), offering potential insights into treatment options and biological patterns of resistance.

Protein Expression 130

Protein Expression Medical Schools Treatment Therapies 130

Drug Discovery World

SEPTEMBER 3, 2024

In this new substudy of the SELECT Trial, researchers looked at whether once-weekly semaglutide (2.4mg) reduced rates of all-cause death, CV death, and non-CV death, including death from Covid-19. However, it has also been associated with an increase in suicidal thoughts.

Medical Schools 147

Medical Schools Trials Disease Hospitals 147

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study conducted by researchers at Harvard Medical School.

Medical Schools 130

Medical Schools Cell Biology Research Therapies 130

Broad Institute

JANUARY 25, 2024

We’ve come to realize recently that there is a lot more information that we can get from our retina images than we thought was possible,” says senior author Nazlee Zebardast, director of glaucoma imaging at Mass Eye and Ear and an assistant professor of ophthalmology at Harvard Medical School.

Disease 124

Disease Research Medical Schools Science 124

Drug Discovery World

JANUARY 9, 2023

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. . The researchers also built a two-layered safety switch into the cancer cell, which can eradicate the therapeutic tumour cells if needed.

Medical Schools 130

Medical Schools Engineering Vaccine Therapies 130

Drug Discovery World

JULY 29, 2022

Isselbacher Professor of Medicine in the Field of Gastroenterology at Harvard Medical School and Massachusetts General Hospital, a core institute member at the Broad Institute of MIT and Harvard, and co-director of the Center for Microbiome Informatics and Therapeutics at MIT. Study after study had suggested that A.

Research 130

Research Immune Response Medical Schools Disease 130

Drug Discovery World

MAY 4, 2023

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. Their research showed that when PD-L1 or PD-L2 interact with another molecule, PD-1, on the surface of T cells, the activity of T cells is kept in check.

Medical Schools 130

Medical Schools Small Molecule Research Treatment 130

Drug Discovery World

APRIL 4, 2023

Join this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space. You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130

RNA Medical Schools Drugs Clinical Trials 130

Drug Discovery World

APRIL 3, 2023

Join this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space. You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130

RNA Medical Schools Drugs Clinical Trials 130

Drug Discovery World

APRIL 18, 2023

Register now. The post Register now to learn how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW).

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

APRIL 11, 2023

Register now. The post Webinar: Find out how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW).

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

APRIL 24, 2023

Register now. The post Free webinar today: How is NGS informing oncology drug discovery?

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

biobide

FEBRUARY 2, 2024

Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. Adapted from a press release issued by Harvard Medical School.

Research 52

Research Immune Response Medical Schools Disease 52

Drug Discovery World

MAY 8, 2024

No medication has been approved by the FDA for vaping cessation in the United States,” said lead author Nancy Rigotti, Director of Massachusetts General Hospital’s Tobacco Research and Treatment Center and a Professor of Medicine at Harvard Medical School.

Clinical Trials 182

Clinical Trials Trials Compliance Drugs 182

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98

RNA Medical Schools Engineering DNA 98

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Broad Institute

AUGUST 19, 2024

A team of researchers at the Broad Institute of MIT and Harvard; the Ragon Institute of Mass General Brigham, MIT, and Harvard; and St. Jude Children’s Research Hospital have discovered that oleic acid, one of the most abundant fatty acids in the body, restores a healthy balance of vaginal microbes in a laboratory model of BV.

Hospitals 121

Hospitals Medical Schools Treatment Science 121

Drug Target Review

SEPTEMBER 14, 2023

Dr Cristina Ureche from Hannover Medical School (MHH) guides us through the aseptic process of viral vector-based vaccines, and Dr Mark J. Dr Brian Kaspar of Insmed Incorporated guides us from bench to bedside, addressing key challenges in gene therapy. Newman of GeoVax, Inc.,

Vaccine 105

Vaccine Medical Schools Drugs Therapies 105

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. However, if the therapy targets only the subclonal (branch) mutations, this will result in the mere ‘pruning’ of specific branches rather than elimination of the whole cancer.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

FEBRUARY 29, 2024

Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development. AskBio) I continue to work to bring innovative gene therapies to patients in need.

Therapies 111

Therapies Disease Clinical Trials Science 111

Broad Institute

APRIL 2, 2024

Now, a team of researchers at the Broad Institute of MIT and Harvard along with Massachusetts General Hospital has found that microbes in the gut may affect cardiovascular disease as well. He is also a professor at Harvard Medical School and Massachusetts General Hospital.

Disease 145

Disease Medical Schools Hospitals DNA 145

The Pharma Data

MAY 17, 2021

. In a Viewpoint, Bishal Gyawali, MD, PhD, and colleagues at the Program on Regulation, Therapeutics and Law (PORTAL) research group at Harvard Medical School and Brigham & Women’s Hospital suggested improving FDA’s authority to modify drug package insert for situations such as drug repurposing and de-escalation of therapy.

Research 52

Research FDA Approval Packaging FDA 52

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both of the new gene therapy studies were published online Dec. SATURDAY, Dec. 5 in the New England Journal of Medicine.

Therapies 52

Therapies Disease Medical Schools Virus 52

Drug Discovery World

APRIL 16, 2023

The randomised KEYNOTE-942 trial assessed the efficacy of mRNA-4157/V940 in prolonging RFS in patients with resected, stages IIIB/IIIC/IIID and IV melanoma when given in combination with pembrolizumab, the standard-of-care adjuvant therapy in this patient population. in the combination arm and 62.2%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Broad Institute

MARCH 8, 2024

It is currently not fully understood why a given person develops the disease or why there is a lot of variation around clinical features across people with the disease,” said senior author Miriam Udler, director of the MGH Diabetes Genetics Clinic, an assistant professor of medicine at Harvard Medical School, and an associate member at Broad.

Medical Schools 127

Medical Schools Hospitals Disease Therapies 127

Nvidia Developer: Drug Discovery

JULY 14, 2022

Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and. The research findings, which included 17 high-confidence and 11 novel therapeutic targets, were recently published in Frontiers in Aging Neuroscience.

Medical Schools 52

Medical Schools Clinical Trials Engineering FDA Approval 52

Broad Institute

NOVEMBER 13, 2023

Doing so would guide treatment decisions, such as whether to continue therapy. "We Such a test could help physicians detect recurrences earlier, intervene sooner, and tailor therapy to each patient. The researchers are also developing, together with the labs of Sangeeta Bhatia and J. Gerstner, Jr.,

DNA 116

DNA Medical Schools Treatment Therapies 116

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Difficult-to-treat and rare, complicated cancers remain a perplexing challenge for IO researchers. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany. Find out more at [link].

Medical Schools 52

Medical Schools Treatment Disease Therapies 52